Patents by Inventor Reinout Stoop

Reinout Stoop has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10578611
    Abstract: The invention relates to the surprising find that low density lipoprotein receptor-deficient mice (LDLr?/?) mice when fed with high energy diets produce controllable and consistent diabetic complications, especially renal damage, similar to the human pathophysiology and biological response. The invention thus comprises a method for discovering a preventive or therapeutic regimen for the prevention or treatment of diabetic micro- or macrovascular complications, comprising the steps of: a. feeding LDLr?/? mice, which have not been treated with streptozotocin, with a high energy diet; b. before, during and/or after this diet treating the mice with the preventive or therapeutic regimen; c. checking whether any change in the micro- or macrovascular system of the animal occurs. Specifically in such a method renal damage is assessed. Also use of said mice fed with a high energy diet for studying the diabetic micro- and macrovascular complications is part of the invention.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: March 3, 2020
    Assignee: Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek TNO
    Inventors: Robert Kleemann, Reinout Stoop, Johan Hendrikus Verheijen, Peter Ydo Wielinga, Teake Kooistra
  • Patent number: 10500154
    Abstract: The invention relates to an injectable biocompatible composition based on a polymeric support as well as to a method for producing it, which composition which comprises at least one hydrophilic polymer, wherein the polymer is polymerizable in situ to form a gel, and wherein the hydrophilic polymer is crosslinkable serum albumin or crosslinkable serum protein. The composition can be used in the restoration, the reconstruction, and/or the replacement of tissues and/or organs, or as a drug release implant in mammals. The composition is particularly suitable for treating cartilage disorders of a diseased or injured articular site in a mammal.
    Type: Grant
    Filed: July 27, 2010
    Date of Patent: December 10, 2019
    Assignee: NMI NATURWISSENSCHAFTLICHES UND MEDIZINISCHES INSTITUT AN DER UNIVERSITAET TUEBINGEN
    Inventors: Juergen Mollenhauer, Karin Benz, Barbara Platz, Helmut Wurst, Reinout Stoop
  • Publication number: 20170363619
    Abstract: The invention relates to the surprising find that low density lipoprotein receptor-deficient mice (LDLr?/?) mice when fed with high energy diets produce controllable and consistent diabetic complications, especially renal damage, similar to the human pathophysiology and biological response. The invention thus comprises a method for discovering a preventive or therapeutic regimen for the prevention or treatment of diabetic micro- or macrovascular complications, comprising the steps of: a. feeding LDLr?/? mice, which have not been treated with streptozotocin, with a high energy diet; b. before, during and/or after this diet treating the mice with the preventive or therapeutic regimen; c. checking whether any change in the micro- or macrovascular system of the animal occurs. Specifically in such a method renal damage is assessed. Also use of said mice fed with a high energy diet for studying the diabetic micro- and macrovascular complications is part of the invention.
    Type: Application
    Filed: June 28, 2017
    Publication date: December 21, 2017
    Inventors: Robert KLEEMANN, Reinout STOOP, Johan Hendrikus VERHEIJEN, Peter Ydo WIELINGA, Teake KOOISTRA
  • Patent number: 9726664
    Abstract: The invention relates to the surprising find that low density lipoprotein receptor-deficient mice (LDLr?/?) mice when fed with high energy diets produce controllable and consistent diabetic complications, especially renal damage, similar to the human pathophysiology and biological response. The invention thus comprises a method for discovering a preventive or therapeutic regimen for the prevention or treatment of diabetic micro- or macrovascular complications, comprising the steps of: a. feeding LDLr?/? mice, which have not been treated with streptozotocin, with a high energy diet; b. before, during and/or after this diet treating the mice with the preventive or therapeutic regimen; c. checking whether any change in the micro- or macrovascular system of the animal occurs. Specifically in such a method renal damage is assessed. Also use of said mice fed with a high energy diet for studying the diabetic micro- and macrovascular complications is part of the invention.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: August 8, 2017
    Assignee: NEDERLANDSE ORGANISATIE VOOR TOEGEPAST—NATUURWETENSCHAPPELIJK ONDERZOEK TNO
    Inventors: Robert Kleemann, Reinout Stoop, Johan Hendrikus Verheijen, Peter Ydo Wielinga, Teake Kooistra
  • Publication number: 20130324423
    Abstract: The invention relates to the surprising find that low density lipoprotein receptor-deficient mice (LDLr?/?) mice when fed with high energy diets produce controllable and consistent diabetic complications, especially renal damage, similar to the human pathophysiology and biological response. The invention thus comprises a method for discovering a preventive or therapeutic regimen for the prevention or treatment of diabetic micro- or macrovascular complications, comprising the steps of: a. feeding LDLr?/? mice, which have not been treated with streptozotocin, with a high energy diet; b. before, during and/or after this diet treating the mice with the preventive or therapeutic regimen; c. checking whether any change in the micro- or macrovascular system of the animal occurs. Specifically in such a method renal damage is assessed. Also use of said mice fed with a high energy diet for studying the diabetic micro- and macrovascular complications is part of the invention.
    Type: Application
    Filed: November 14, 2011
    Publication date: December 5, 2013
    Inventors: Robert Kleemann, Reinout Stoop, Johan Hendrikus Verheijen, Peter Ydo Wielinga, Teake Kooistra
  • Publication number: 20100322993
    Abstract: The invention relates to an injectable biocompatible composition based on a polymeric support as well as to a method for producing it, which composition which comprises at least one hydrophilic polymer, wherein the polymer is polymerizable in situ to form a gel, and wherein the hydrophilic polymer is crosslinkable serum albumin or crosslinkable serum protein. The composition can be used in the restoration, the reconstruction, and/or the replacement of tissues and/or organs, or as a drug release implant in mammals. The composition is particularly suitable for treating cartilage disorders of a diseased or injured articular site in a mammal.
    Type: Application
    Filed: July 27, 2010
    Publication date: December 23, 2010
    Inventors: Juergen Mollenhauer, Karin Benz, Barbara Platz, Helmut Wurst, Reinout Stoop
  • Publication number: 20100291179
    Abstract: The present invention relates to a composite biomaterial and a process for producing a composite biomaterial with controlled release of active ingredients, comprising a three-dimensional polymer-based support structure, and a polymer-based matrix structure. The active ingredients are in this case incorporated into the composite biomaterial via the matrix structure, and the composite biomaterial is obtainable by introducing the matrix structure into the support structure. The active ingredients may in this case be incorporated for example adhesively, via specific binder molecules or via enzyme-labile linker molecules via the matrix structure into the composite biomaterial.
    Type: Application
    Filed: April 16, 2010
    Publication date: November 18, 2010
    Inventors: Dieter Stoll, Reinout Stoop, Juliana Vaz Nürnberger, Christoph Gaissmaier, Michael Ahlers, Claudia Bohnsack